One marked difference that sets MOG antibody-associated demyelination apart from both MS and AQP4 antibody-positive demyelination is the prognostic concerns, leading to the different amounts of aggressiveness in terms of management and treatment [7]. The gene discussed is MOG; the disease is myeloid sarcoma.